Skip to content

Study · Animal study (in vivo) · mouse · 2013

3 results

B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide.

Liu Z, Gao X, Kang T, Jiang M, Miao D, Gu G, Hu Q, Song Q, Yao L, Tu Y, Chen H, Jiang X, Chen J

Bioconjugate chemistry10 Jun 2013Cited by 107 (Europe PMC)

PMID23718945 (opens in a new tab)DOI10.1021/bc400055h (opens in a new tab)PepBankPUB-23718945
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Alzheimer's disease mouse models, B6 nanoparticle-encapsulated NAP ameliorated learning impairments even at a lower dose.

    In plain wordsIn mice with Alzheimer's disease models, NAP in B6 nanoparticles reduced learning problems even at a lower dose.

    Peptide
    Davunetide
    Outcome
    DecreaseLearning impairments
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Administration of B6-NP encapsulated neuroprotective peptide-NAPVSIPQ (NAP)-to Alzheimer's disease mouse models showed excellent amelioration in learning impairments, cholinergic disruption, and loss of hippocampal neurons even at lower dose.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Alzheimer's disease mouse models, B6 nanoparticle-encapsulated NAP ameliorated cholinergic disruption even at a lower dose.

    In plain wordsIn mice with Alzheimer's disease models, NAP in B6 nanoparticles reduced cholinergic disruption even at a lower dose.

    Peptide
    Davunetide
    Outcome
    DecreaseCholinergic disruption
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Administration of B6-NP encapsulated neuroprotective peptide-NAPVSIPQ (NAP)-to Alzheimer's disease mouse models showed excellent amelioration in learning impairments, cholinergic disruption, and loss of hippocampal neurons even at lower dose.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Alzheimer's disease mouse models, B6 nanoparticle-encapsulated NAP ameliorated hippocampal neuron loss even at a lower dose.

    In plain wordsIn mice with Alzheimer's disease models, NAP in B6 nanoparticles reduced hippocampal neuron loss even at a lower dose.

    Peptide
    Davunetide
    Outcome
    DecreaseHippocampal neuron loss
    Study

    mousen: not reported in source

    Alzheimer's disease mouse models
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Administration of B6-NP encapsulated neuroprotective peptide-NAPVSIPQ (NAP)-to Alzheimer's disease mouse models showed excellent amelioration in learning impairments, cholinergic disruption, and loss of hippocampal neurons even at lower dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.